Cargando…

SARS-CoV-2 Infectivity and Severity of COVID-19 According to SARS-CoV-2 Variants: Current Evidence

Background: We conducted this review to summarize the relation between viral mutation and infectivity of SARS-CoV-2 and also the severity of COVID-19 in vivo and in vitro. Method: Articles were identified through a literature search until 31 May 2021, in PubMed, Web of Science and Google Scholar. Re...

Descripción completa

Detalles Bibliográficos
Autores principales: Dao, Thi Loi, Hoang, Van Thuan, Colson, Philippe, Lagier, Jean Christophe, Million, Matthieu, Raoult, Didier, Levasseur, Anthony, Gautret, Philippe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8232800/
https://www.ncbi.nlm.nih.gov/pubmed/34203844
http://dx.doi.org/10.3390/jcm10122635
_version_ 1783713716347338752
author Dao, Thi Loi
Hoang, Van Thuan
Colson, Philippe
Lagier, Jean Christophe
Million, Matthieu
Raoult, Didier
Levasseur, Anthony
Gautret, Philippe
author_facet Dao, Thi Loi
Hoang, Van Thuan
Colson, Philippe
Lagier, Jean Christophe
Million, Matthieu
Raoult, Didier
Levasseur, Anthony
Gautret, Philippe
author_sort Dao, Thi Loi
collection PubMed
description Background: We conducted this review to summarize the relation between viral mutation and infectivity of SARS-CoV-2 and also the severity of COVID-19 in vivo and in vitro. Method: Articles were identified through a literature search until 31 May 2021, in PubMed, Web of Science and Google Scholar. Results: Sixty-three studies were included. To date, most studies showed that the viral mutations, especially the D614G variant, correlate with a higher infectivity than the wild-type virus. However, the evidence of the association between viral mutation and severity of the disease is scant. A SARS-CoV-2 variant with a 382-nucleotide deletion was associated with less severe infection in patients. The 11,083G > U mutation was significantly associated with asymptomatic patients. By contrast, ORF1ab 4715L and S protein 614G variants were significantly more frequent in patients from countries where high fatality rates were also reported. The current evidence showed that variants of concern have led to increased infectivity and deteriorating epidemiological situations. However, the relation between this variant and severity of COVID-19 infection was contradictory. Conclusion: The COVID-19 pandemic continues to spread worldwide. It is necessary to anticipate large clinical cohorts to evaluate the virulence and transmissibility of SARS-CoV-2 mutants.
format Online
Article
Text
id pubmed-8232800
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-82328002021-06-26 SARS-CoV-2 Infectivity and Severity of COVID-19 According to SARS-CoV-2 Variants: Current Evidence Dao, Thi Loi Hoang, Van Thuan Colson, Philippe Lagier, Jean Christophe Million, Matthieu Raoult, Didier Levasseur, Anthony Gautret, Philippe J Clin Med Review Background: We conducted this review to summarize the relation between viral mutation and infectivity of SARS-CoV-2 and also the severity of COVID-19 in vivo and in vitro. Method: Articles were identified through a literature search until 31 May 2021, in PubMed, Web of Science and Google Scholar. Results: Sixty-three studies were included. To date, most studies showed that the viral mutations, especially the D614G variant, correlate with a higher infectivity than the wild-type virus. However, the evidence of the association between viral mutation and severity of the disease is scant. A SARS-CoV-2 variant with a 382-nucleotide deletion was associated with less severe infection in patients. The 11,083G > U mutation was significantly associated with asymptomatic patients. By contrast, ORF1ab 4715L and S protein 614G variants were significantly more frequent in patients from countries where high fatality rates were also reported. The current evidence showed that variants of concern have led to increased infectivity and deteriorating epidemiological situations. However, the relation between this variant and severity of COVID-19 infection was contradictory. Conclusion: The COVID-19 pandemic continues to spread worldwide. It is necessary to anticipate large clinical cohorts to evaluate the virulence and transmissibility of SARS-CoV-2 mutants. MDPI 2021-06-15 /pmc/articles/PMC8232800/ /pubmed/34203844 http://dx.doi.org/10.3390/jcm10122635 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Dao, Thi Loi
Hoang, Van Thuan
Colson, Philippe
Lagier, Jean Christophe
Million, Matthieu
Raoult, Didier
Levasseur, Anthony
Gautret, Philippe
SARS-CoV-2 Infectivity and Severity of COVID-19 According to SARS-CoV-2 Variants: Current Evidence
title SARS-CoV-2 Infectivity and Severity of COVID-19 According to SARS-CoV-2 Variants: Current Evidence
title_full SARS-CoV-2 Infectivity and Severity of COVID-19 According to SARS-CoV-2 Variants: Current Evidence
title_fullStr SARS-CoV-2 Infectivity and Severity of COVID-19 According to SARS-CoV-2 Variants: Current Evidence
title_full_unstemmed SARS-CoV-2 Infectivity and Severity of COVID-19 According to SARS-CoV-2 Variants: Current Evidence
title_short SARS-CoV-2 Infectivity and Severity of COVID-19 According to SARS-CoV-2 Variants: Current Evidence
title_sort sars-cov-2 infectivity and severity of covid-19 according to sars-cov-2 variants: current evidence
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8232800/
https://www.ncbi.nlm.nih.gov/pubmed/34203844
http://dx.doi.org/10.3390/jcm10122635
work_keys_str_mv AT daothiloi sarscov2infectivityandseverityofcovid19accordingtosarscov2variantscurrentevidence
AT hoangvanthuan sarscov2infectivityandseverityofcovid19accordingtosarscov2variantscurrentevidence
AT colsonphilippe sarscov2infectivityandseverityofcovid19accordingtosarscov2variantscurrentevidence
AT lagierjeanchristophe sarscov2infectivityandseverityofcovid19accordingtosarscov2variantscurrentevidence
AT millionmatthieu sarscov2infectivityandseverityofcovid19accordingtosarscov2variantscurrentevidence
AT raoultdidier sarscov2infectivityandseverityofcovid19accordingtosarscov2variantscurrentevidence
AT levasseuranthony sarscov2infectivityandseverityofcovid19accordingtosarscov2variantscurrentevidence
AT gautretphilippe sarscov2infectivityandseverityofcovid19accordingtosarscov2variantscurrentevidence